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device use days of 1.3 for the LifeSite alcohol group, 3.3 for theMulticenter clinical trial results with the LifeSite hemodialysis
Tesio-Cath group, and 3.4 per for the LifeSite oxychloroseneaccess system.
group. There was no statistically significant difference in deviceBackground. The LifeSite Hemodialysis Access System is
related infection rates between the Tesio-Cath and the LifeSitea subcutaneous access device designed to maximize blood flow
oxychlorosene groups. There were significant differences inwhile minimizing access-related complications. The purpose of
this study was to compare the efficacy and safety of the LifeSite infection rate between LifeSite alcohol group and the other
System to a similar but transcutaneous access device, the Tesio- two groups (P  0.05). Device thrombosis was defined by the
Cath Hemodialysis Catheter. need for instillation of thrombolytic agents to maintain blood
Methods. The study was conducted in two phases. A multi- flow 300 mL/min. There was no difference in the need for
center randomized prospective design was utilized for the first thrombolytic infusions between the LifeSite oxychlorosene
phase (Phase 1) where thirty-four patients were enrolled in group and the Tesio-Cath group (P  0.1496); however, the
the Tesio-Cath group and 36 patients into the LifeSite group LifeSite alcohol group required significantly fewer thrombo-
where 0.2% sodium oxychlorosene was used as an antimicro- lytic infusions than the Tesio-Cath group (P 0.0295) to main-
bial solution for the LifeSite. A nonrandomized, but otherwise tain adequate blood flow. Device survival at 6 months after
identical, second phase of the study followed where a 70% stratification by diabetic status and adjusting for age was sig-
isopropyl alcohol solution was utilized as the antimicrobial nificantly better in the LifeSite alcohol group (89.9%) than in
solution for 34 additional LifeSite patients (Phase 2). the LifeSite oxychlorosene group (64.8%, P  0.0286) and in
Results. Device function was evaluated in Phase 1 of the the Tesio-Cath (69.1%, P  0.0292) group.
trial. Actual blood flow (determined by ultrasound dilution) Conclusions. The LifeSite Hemodialysis Access System,
was greater in the LifeSite versus the Tesio-Cath group (358.7 when used with 70% isopropyl alcohol as an antimicrobial
vs. 331.8 mL/min, P  0.001 for machine-indicated blood flow solution, provides superior performance with a lower infection
of 400 mL/min). Infection comparisons were performed for all rate and better device survival than a standard cuffed tunneled
three groups encompassing Phase 1 and 2 of the trial; Tesio- hemodialysis catheter.
Catheter, LifeSite System with oxychlorosene, and LifeSite
System with 70% isopropyl alcohol. Device-related infections
were defined as systemic bacteremia without another obvious
Central venous catheters have been in use for hemodi-site of origin and exit site infections requiring systemic antibiot-
ics or device removal. This revealed infection rates per 1000 alysis for over 20 years and are used at an ever-increasing
rate in the United States [1]. In 1996, more than 30%
of all new hemodialysis patients received dialysis through
1 Current address: Emory University School of Medicine, Atlanta, GA. a catheter 60 days after commencing treatment [2]. While2 Current address: University of Maryland Medical Center, Balti-
catheters present an attractive alternative for immediatemore, MD.
and short-term hemodialysis access, they are often asso-
Key words: vascular access, hemodialysis, dialysis catheter, subcutane-
ciated with erratic performance characterized by poorous access device, transcutaneous access device, cuffed tunneled hemo-
dialysis catheter. blood flow, frequent thrombosis and high rates of infec-
tion resulting in hospitalization [1, 3]. Infection requiring
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METHODS
Materials
Hemodialysis vascular access was provided via the
LifeSite System (2 devices) or a Tesio-Cath cuffed tun-
neled dialysis catheter system (2 catheters; Med Comp,
Harleysville, PA, USA) for study patients. The proce-
dure for utilizing the LifeSite System for hemodialysis
was as follows. The skin surface over the valve was first
cleansed with a 4% chlorhexidrine or equivalent solu-
tion. The LifeSite valve and buttonhole tracts were then
irrigated with an antimicrobial solution using a 25-gauge
needle (Fig. 3). The insertion of the 25-gauge needle
into the valve does not actuate the internal pinch clamp.
After irrigation with the antimicrobial solution, a 14-
gauge fistula needle was inserted into the valve, allowing
for blood flow (Fig. 2). At the end of the dialysis session
the cannulas are locked with heparin and the 14-gauge
fistula needles were removed. The antimicrobial irriga-
tion step was then repeated. The procedure for utilizing
the Tesio-Cath device was based on the manufacturer’s
recommendations, and involves a clean connect discon-
nect procedure and heparin instillation into the catheter
at the end of the hemodialysis treatment.
Fig. 1. The LifeSite Hemodialysis Access System.
Study design
This clinical study consisted of two phases (Fig. 4).
Phase 1. An open-label, prospective, multi-center,venous hemodialysis access is theoretically very desir-
randomized clinical design where the LifeSite Systemable. Two such access systems have been developed and
was compared concurrently to the Tesio-Cath hemodial-pilot studies have been reported: the LifeSite Hemodi-
ysis catheter. In this initial phase 0.2% sodium oxychloro-alysis Access System (Vasca, Inc., Tewksbury, MA, USA)
sene (Clorpactin; United Guardian, Hauppauge, NY,and the Dialock Access System (Biolink Inc., Norwell,
USA) was used as the antimicrobial agent for the Life-MA, USA) [4–6].
Site valve.The LifeSite System is a fully subcutaneous venous
Phase 2. A non-randomized extension phase in whichaccess device that is designed for reliable, repetitive,
70% isopropyl alcohol (IPA) was used as the antimicro-high-flow hemodialysis access. The device consists of a
bial agent. Phase 2 directly followed Phase 1 and wasvalve, which is typically implanted below the clavicle,
limited to the enrollment of LifeSite patients, with theand a silicone cannula preferably tunneled to the right
only difference being the antimicrobial solution used.internal jugular vein (Fig. 1). A 14-gauge dialysis needle
Phase 2 was performed to evaluate the efficacy of 70%(Medisystems, Seattle, WA, USA) is used to access the
IPA as the antimicrobial solution used with the LifeSitedevice and actuates an internal pinch clamp inside the
System after sodium oxychlorosene was found to havevalve (Fig. 2). When the needle is removed, the pinch
inferior in vitro bactericidal effect against commonly oc-clamp closes, stopping flow. The LifeSite System uses
curring gram-positive organisms (Staphylococcus andnew unique access techniques. The LifeSite System is
Streptococcus species) compared with isopropyl alcoholaccessed via the same site each session using the button-
[7]. Phase 2 differed from Phase 1 by enrolling only Life-hole technique (abstract; Twandowski ZJ, Dial Transplant
Site patients and by the substitution of 70% IPA as the24:559, 1995). Two devices are typically implanted, one
antimicrobial solution used to irrigate the LifeSite valvefor draw and one for return of blood during hemodialysis.
and buttonhole tract. This phase of the study was focusedA novel in vivo disinfecting procedure of the valve, tissue
on device infection since the antimicrobial agent shouldpocket and buttonhole is performed before and after
have no effect on device efficacy.each use (Fig. 3). Based on the results of the initial pilot
All patients at the participating centers who requiredstudies with the LifeSite System [4], this prospective,
immediate vascular access for hemodialysis while awaitingmulticenter clinical study was designed to evaluate the
maturation or surgical creation of a permanent arteriove-efficacy and safety of the LifeSite Hemodialysis Access
System compared to a standard hemodialysis catheter. nous fistula or graft were eligible for randomization to
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Fig. 2. Cross-sectional view of LifeSite valve
(A) prior to actuation with a 14-gauge fistula
needle and (B ) following actuation with a
14-gauge fistula needle.
Fig. 4. Study design.
were based on the Student t test and the Wilcoxon rank
sum test, or mixed model was used to account for re-
peated measurements.
Rates of events were analyzed using the Poisson re-
gression technique. If significant overdispersion was de-
tected, then an adjustment was done by multiplying theFig. 3. A 25-gauge needle inserted into valve for delivery of antimicro-
covariance matrix of estimated regression coefficients bybial solution.
a dispersion parameter [8], or event counts were ana-
lyzed using negative binomial regression when appro-
LifeSite or Tesio-Cath groups provided they met the priate. Rates were computed as the number of events
criteria reported in Table 1. The trial was conducted in per patient-month. Adjustments for within subject corre-
14 centers in the U.S. and began in June 1998. Subjects lations between repeated counts (by using Generalized
were followed until the device was explanted, death or Estimating Equations), time trend and significant prog-
until six months after implantation. Patients received nostic factors were performed when appropriate.
their routine hemodialysis therapy throughout the study Device survival analysis for all implanted LifeSite and
as prescribed by the patients’ nephrologists. The princi- Tesio-Cath devices was performed with Kaplan-Meier
pal investigator and/or staff members described the na- technique, after stratification by diabetes status and ad-
ture of the study to potential study subjects and ensured justing for age. The device survival times were censored
that all requirements for informed consent were met. for planned removals (bridge to permanent access, trans-
The study was approved by the appropriate Investigation plant) and for non-device related deaths.
Review Board (IRB) at each of the participating centers. All reported P-values are two-sided. A P-value 0.05
The inclusion and exclusion criteria were unchanged for was considered to indicate statistical significance. No
Phase 2 of the study and the study modification described adjustments for multiple comparisons were made. Calcu-
above was approved by the IRBs at the study centers. lations were performed using version 8.1 SAS software
(2000; SAS Institute Inc., Cary, NC, USA).
Statistical analyses
PatientsFor discrete variables, Pearson chi-square and Fisher’s
exact test were used to compare the baseline characteris- The study population for Phase 1 consisted of patients
with end-stage renal disease (ESRD) who required he-tics of patients in the LifeSite and Tesio-Cath groups.
Comparisons of continuous measurements between groups modialysis and were appropriate candidates for both the
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Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Subject requires immediate vascular access for hemodialysis while Any infection associated with one or more positive blood culturesawaiting maturation or surgical creation of a permanent arteriovenous within 10 days prior to planned implantationafistula or graft
Subject is 18 years old Presence of a systemic or localized infection that is unresponsiveto antibiotic therapy and/or is life threatening
Subject requires treatment 3 times per week at a hemodialysis treatment Any infection associated with the implantation site (e.g., exit site
center infection associated with a previous catheter)
Subject has a history of compliance with a dialysis treatment schedule Local tissue factors that will prevent proper device stabilization
or, if a new patient, expresses willingness to be compliant with the treatment and/or access (e.g., lack of adequate subcutaneous tissue to stabilize
schedule the port or catheter)
Subject plans to continue hemodialysis treatment and follow-up at the Subject has a known or suspected allergy to the device materials
investigational site (titanium alloy, stainless steel or silicone)
Subject is able to care for the exit site independently Subject is pregnant
Subject has provided informed consent Subject is a known intravenous drug abuser
a Patients not eligible until 10 to 14 days after blood cultures have become negative and clinical resolution of the infectious episode has occurred
Table 2. Patient demographics groups (Phase 1 or 2) with respect to baseline demo-
graphic characteristics (Table 2) with an exception forPhase 1 Phase 1 Extension
LifeSite Tesio-Cath LifeSite a higher percentage of patients with a history of musculo-
Patient characteristic (N  36) (N  34) (N  34)
skeletal conditions in the LifeSite alcohol group (73.5%)
Age years compared to the LifeSite oxychlorosene (50%, P MeanSD 54.116.4 57.815.9 58.414.1
0.0432) or Tesio-Cath groups (41.2%, P  0.0136).Range min, max 28, 79 24, 82 28, 82
Estimated dry weight kg 72.430.6 79.230.1 83.516
(43, 125) (50, 200) (48.2, 123) Surgical procedures
Gender
Males 13 (36.1%) 17 (50%) 21 (61.8%) The LifeSite System was placed following a standard-
Females 23 (63.9%) 17 (50%) 13 (38.2%) ized implant protocol with preferred implantation in the
Race
jugular vein(s) using the Seldinger technique. Each valveCaucasian 11 (30.6%) 9 (26.5%) 13 (38.2%)
African American 23 (63.9%) 23 (67.6%) 20 (58.8%) was placed within a separate subcutaneous tissue pocket
Asian 36 (0%) 1 (2.9%) 0 (0%) created below the clavicle. The cannulas were insertedHispanic 1 (2.8%) 1 (2.9%) 1 (2.9%)
using real-time ultrasound guidance. Fluoroscopy wasOther 1 (2.8%) 0 (0%) 0 (0%)
Primary cause of ESRD used to confirm proper placement of the cannula tips.
Glomerulonephritis 0 (0%) 2 (5.9%) 0 (0%)
The distal or blood return tip was placed in the rightDiabetes 20 (55.6%) 19 (55.9%) 24 (70.6%)
Hypertension 11 (30.6%) 8 (23.5%) 6 (17.6%) atrium and the proximal or blood withdrawal tip was
Other 5 (13.9%) 5 (14.7%) 4 (11.8%) placed 2 cm superior at the atrial caval junction or the
right atrium. Placement was conducted under conscious
sedation and local anesthesia. Two LifeSite devices were
LifeSite and the Tesio-Cath devices. Seventy-nine pa- used for each patient in this study to allow dual needle
tients were randomized using a central randomization hemodialysis. Twenty-seven (38.6%) of the LifeSite de-
scheme. Of these, 70 patients were implanted with either vices were implanted by interventional nephrologists, 24
the LifeSite (N  36) or Tesio-Cath devices (N  34).
(34.3%) by interventional radiologists and 19 (27.1%)Nine randomized patients did not receive a device be-
by vascular surgeons. Fifty-three (75.6%) of the LifeSitecause of occluded vessels (N  3); exclusion criteria
devices were implanted in a vascular suite and 17 (24.3%)violation (N 2); patient withdrawal of consent (N 2);
were implanted in an operating room. Tesio-Cath devicesmedical decision by physician (N 1); or administrative
were implanted in accordance with the manufacturer’sreasons (N  1).
instructions for use. Two Tesio-Caths were implanted inAn additional 34 consecutive patients who met the
each patient with placement of the catheter tips in similarsame inclusion and exclusion criteria were implanted
position to the LifeSites’ position. Real time ultrasoundwith the LifeSite System during Phase 2 of the study
for insertion and fluoroscopy for tip placement werewhere 70% IPA was used as the antimicrobial solution.
done for all insertions. Nine (26.5%) of the Tesio-CathsAnalyses are presented using data from these patients
were implanted by interventional nephrologists, 17 (50.0%)compared to the 34 Tesio-Cath patients from Phase 1.
by interventional radiologists and 8 (23.5%) by vascularNo statistically or clinically significant differences existed
between the Tesio-Cath patients or either of the LifeSite surgeons. Thirty (88.2%) of the Tesio-Caths were im-
Schwab et al: LifeSite venous access1030
planted in a vascular suite and 4 (11.8%) were implanted
in an operating room.
Function analysis
The function analysis was based on monthly determi-
nations in the initial randomized phase (Phase 1) of the
study. The primary function outcome variable was actual
blood flow within acceptable machine limits (that is, draw
pressure 300 mm Hg and return pressure 450
mm Hg). For these comparisons, the blood pump was
set to achieve targeted machine-indicated blood flow
rates (Qb) of 100 to 500 mL/min and where technically
achievable, 600 mL/min. The actual flow rate delivered
at these settings was determined by ultrasound indicator
Fig. 5. Actual blood flow versus machine-indicated blood flow. Thedilution [9] using the Transonic HD01 Hemodialysis
solid line represents the line of identity.Monitor (Transonic Inc., Ithaca, NY, USA). Dialysis
clearance (mean Kt/V) also was determined monthly
using a single-pool variable volume model [10] recom-
pressure 450 mm Hg). These data were obtained from
mended in the NKF-DOQI Clinical Practice Guide-
monthly measurements in Phase 1 of the study. Compari-lines for Hemodialysis Adequacy [11].
sons of targeted machine-indicated blood flow rates to
actual blood flow rates measured using the TransonicInfection analysis
HD01 Hemodialysis Monitor [9] are shown in Figure 5.The infection analysis was based on six-month follow-
The blood flow rates were significantly higher for theup data for 36 LifeSite patients from Phase 1 where
LifeSite System compared to the Tesio-Cath device (358.7oxychlorosene was used as the antimicrobial solution,
vs. 331.8 mL/min, P 0.001 for machine indicated bloodand 34 LifeSite patients from the second non-random-
flow of 400 mL/min). As can be seen in Figure 5, theized phase of the study where isopropyl alcohol was
true blood flow rates between LifeSite and Tesio-Cathused as the antimicrobial agent. These patients were
devices rapidly increases along with the increase in ma-compared to the 34 Tesio-Cath patients from Phase 1.
chine-indicated blood flow rates, demonstrating that theThe infection outcome variable analyzed was device-
actual blood flow rate delivered with the LifeSite systemrelated infection defined as systemic bacteremia or exit
more accurately reflects the desired blood flow rate.site infection requiring systemic antibiotic therapy or
As additional measures of device efficacy, analyses ofdevice removal.
dialysis clearance (Kt/V) and dialysis time were per-
formed monthly during phase one of the study. TheDysfunction analysis
differences between the LifeSite system and Tesio-CathDevice dysfunction was tracked in both Phase 1 and
device with respect to Kt/V and mean dialysis time werePhase 2 of the study and was defined by need for throm-
not statistically significant, although there was a strongbolytic agent use. Access flows less than 300 mL/min
trend for longer treatment times (P 0.073) for patientsor complete occlusion of the device were treated via
in the Tesio-Cath group.instillation of either tissue plasminogen activator (tPA)
1 mg/mL or urokinase 5000 U/mL. A volume of the
Infectionthrombolytic agent sufficient to completely fill the cathe-
Analyses of infection parameters were performedter lumen was utilized and allowed to dwell for either
comparing results from the 36 LifeSite oxychorosenefour hours or overnight based on patients status and
patients and the 34 LifeSite alcohol patients to the 34unit preference. The use of the thrombolytic agent was
Tesio-Cath patients. As shown in Figure 6, LifeSite alco-limited to the occluded lumen only.
hol patients consistently experienced a statistically sig-
nificant lower rate of infection events (bacteremia and
RESULTS device related infection) compared to the patients in the
Function Tesio-Cath group or the LifeSite oxychlorosene group.
There were no differences in infection rate between theThe primary function of the LifeSite System and the
LifeSite oxychlorosene group and the Tesio-Cath group.Tesio-Cath device was determined based on the ability to
Table 3 reports the infecting organisms by site of infec-deliver an adequate blood flow rate during hemodialysis
tion for each group. There were 18 episodes of bacter-while maintaining acceptable draw (arterial pressure less
negative than 300 mm Hg) and return pressures (venous emia and no local infections in the LifeSite oxychloro-
Schwab et al: LifeSite venous access 1031
Fig. 7. Technical device survival.
Fig. 6. Comparison of device-related infections in the LifeSite alcohol
(N  34), LifeSite oxychlorosene (N  36) and Tesio-Catheter (N 
34) groups. *P  0.05 versus both LifeSite oxychlorosene and Tesio-
When viewed as device specific (LifeSite vs. Tesio Cath)Catheter groups.
there were no differences in overall thrombolytic agent
use (9.01 vs. 8.81 infusions per 1000 patient-days; P 
Table 3. Device-related infections
NS). However, when analyzed separately, the LifeSite
Number Organisms (N) alcohol group required significantly fewer thrombolytic
LifeSite alcohol (N  34) — infusions compared to the Tesio Cath group (2.27 vs.
Local infections 0 8.81 infusions per 1000 patient-days; P  0.0295).Bacteremias 6 Staph epidermidis (5)
Proteus
Device survivalLifeSite oxychlorosene
(N  36) — Overall device survival was evaluated up to 6 monthsLocal infections 0
(182 days). All devices in all three groups were evaluatedBacteremias 18 Staph epidermidis (11)
Methicillin-resistant Staph epi and are depicted in Figure 7. The Kaplan-Meier esti-
Staph aureus mates of the 6-month device survival rate were 89.9%E. coli
for the LifeSite alcohol group, 64.8% for the LifeSiteProteus mirabilis (2)
Klebsiella pneumoniae oxychlorosene group and 69.1% in the Tesio-Cath group.
Candida albicans In addition, after stratification by diabetes status and age,Tesio-Cath (N  34)
the 6-month survival rate was statistically significantlyLocal infections 4 Staph epidermidis
Staph aureus better in the LifeSite alcohol group than in both the
Yeast
LifeSite oxychlorosene group (P  0.0286) and theNegative culture
Bacteremias 13 Staph epidermidis (3) Tesio-Cath group (P 0.0292). There were no significant
Staph aureus (3) differences in 6-month patient survival.
Methicillin-resistant Staph
aureus (2)
Enterobacter cloacae
DISCUSSIONKlebsiella oxytoca
Klebsiella pneumoniae Vascular access remains the largest single cause of
Mixed Klebsiella pneumoniae
morbidity in the hemodialysis population in the United& E. coli
Mixed Ps. aeruginosa, E. coli, States despite national efforts to improve access plan-
MRSA ning, placement, and care [12]. The ideal access would
provide reliable high blood flow rates to optimize dialysis
delivery while minimizing complications. Tunneled cath-
eters continue to be used at a high rate for hemodialysissene group, 13 episodes of bacteremia and 4 local
while their use continues to be associated with increasedinfections in the Tesio-Cath group, and 6 episodes of
morbidity and costs [1]. Catheter use also results in de-bacteremia and no local infections in the LifeSite with
creased delivered hemodialysis due to flow limitationsalcohol group.
compared to arteriovenous fistulas or polytetrafluore-
Device dysfunction thylene (PTFE) grafts [13]. Infection in cuffed catheters
is significant and remains the primary barrier to long-Device dysfunction was defined by need for thrombo-
lytic instillation in both Phase 1 and Phase 2 of the study. term catheter use [1].
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Subcutaneous venous dialysis access systems have been two devices tested (Lifesite vs. Tesio-Cath) when Phase
1 and 2 data were combined, however, there were differ-developed in attempt to overcome many of the short-
comings associated with hemodialysis catheters. Two ences between Phase 1 and 2 of the study. In Phase 1
of the study, the Lifesite oxychlorosene similar numberssuch systems, the LifeSite Hemodialysis Access System
and the Dialock Access System, have undergone pilot of thrombolytic infusions compared with the Tesio group
but in Phase 2 the Lifesite alcohol group required fewerstudies and clinical trials. The initial pilot study of the
LifeSite System showed the promise of this class of sub- thrombolytic infusions than the Tesio group (P 0.0295).
The reasons for this difference in the need for thrombo-cutaneous devices, but as with most pilot trials, had a
higher complication rate than outlined in this compara- lytic infusions between the two LifeSite groups are un-
clear. This difference may have been related to the learn-tive trial [4]. This is not surprising given that the pilot
trial defined the techniques that emerged to be used in ing curve associated with use of the device or a result
of the use of oxychlorosene.this study and the use of oxychlorosene instead of IPA
as the antimicrobial agent used in conjunction with the Infectious complications associated with the use of he-
modialysis catheters are a significant cause of morbidityLifeSite System. This study represents the first multi-
center comparative clinical trial of the LifeSite System. and hospitalization [12]. Indeed in most studies infection
remains the barrier to long-term catheter use. The preva-This study demonstrates that multiple centers were
capable of inserting and using the LifeSite System with- lence of catheter-associated bacteremia has been re-
ported to between two to four per 1000 patient-days [1,out difficulty. The study also clearly demonstrated that
the LifeSite System can be placed in vascular suites by 15–17]. The LifeSite alcohol group was associated with
a statistically significantly lower rate of device relatednephrologists, surgeons, and radiologists, or can be
placed in the operating room in instances where vascular infectious complications compared to the Tesio-Cath de-
vice in this study. LifeSite alcohol patients experiencedsuites are not available. Nonetheless, as clearly outlined
by the differences in the pilot and comparative trial, one device-related infection per 26.9 patient-months (1.3
per 1000 patient-days) compared to one infection perthere is a learning curve and a skill factor associated
with the insertion and use of this new technology. It is 10.1 patient-months (3.3 per 1000 patient-days) for the
Tesio-Cath group and 10.3 patient-months (3.4 per 1000important to insure the device is properly implanted and
that dialysis units receive specific training on the correct patient-days) for the LifeSite oxychlorosene group. The
device-related infection rate observed in our currentcare and maintenance for this device. It is our belief that
improper implantation or inadequate staff training will study for the Tesio-Cath and LifeSite oxychlorosene de-
vice was similar to that reported in other studies forresult in increased device-related complications.
The machine-indicated blood flow rates for both the cuffed tunneled catheters [16–18].
The reduced incidence of infection observed in theLifeSite System and the Tesio-Cath overestimated actual
blood flow rates in our study (Fig. 5). The error was larger LifeSite patients is likely due to several factors. First,
the subcutaneous placement of the LifeSite valves maywith the Tesio-Cath, becoming statistically significant at
flow rates200 mL/min, and increased progressively with reduce the potential for infections as opposed to an exter-
nalized catheter device. However, as was seen in thehigher blood flow rates. The increased flow rate with the
LifeSite System is in part due to the larger diameter LifeSite oxychlorosene group, this alone may not be
sufficient as there is always a residual space at the portof the cannula (12 French), which is connected to the
implanted valve compared to the 10 French diameter pocket that requires sterilization. Fortunately, the unique
design of the LifeSite valves allows the instillation offor the Tesio-Cath. The design of the LifeSite System
and the use of a 14-gauge enable the maintenance of a an antimicrobial agent to fill this subcutaneous pocket,
which comprises the valve, valve pocket, and buttonholehigh flow rate with no increase in hemolysis [14]. The
difference between the dialysis clearance (Kt/V) deliv- tract. The choice of antimicrobial agent seems quite im-
portant as it must be effective against the likely infectingered in LifeSite and Tesio-Cath groups was not statisti-
cally significant. This was expected, since dialysis clear- organisms. As was apparent in this study 70% IPA solu-
tion was remarkably effective whereas the oxychloroseneance is prescribed, monitored, and adjusted by the
treating clinician for the individual patient. There was, solution was not effective. IPA has substantially better
in vitro bactericidal performance (data on file) comparedhowever, a strong trend for longer dialysis treatment
time in the Tesio-Cath group compared to the LifeSite with oxychlorosene. IPA is a readily available, inexpen-
sive antimicrobial solution that has a documented abilityGroup (3.6 0.5 vs. 3.8 0.5 hours; P 0.073), reflecting
the need to adjust for the reduced actual blood flow to control bacteria (Staphylococcus and Streptococcus
species), the primary cause of infection in hemodialysisrate required to reach the prescribed dialysis dose in all
treatment groups. patients [19]. Thus, it is both the antimicrobial agent and
the subcutaneous nature of the device that led to theOverall device dysfunction as defined by need for
thrombolytic instillation was not different between the lowered device related infection rate for the LifeSite
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System compared both to nationally published data for increasing arteriovenous fistula usage in accordance with
the K/DOQI recommendations [21].external catheters and the control group (Tesio-Cath)
in this study.
There was improved device survival in the LifeSite ACKNOWLEDGMENT
alcohol group compared to the other two groups (Fig. This study was supported through a research grant from Vasca, Inc.
7). This has important implications for long-term hemo-
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